No. | Age, y | Gender | TNM | KPS a | Tumors | Size, cm3 | Seeds b; activity, mCi | MPD, Gy |
---|---|---|---|---|---|---|---|---|
1 | 72 | M | T3N1M0 | 70 | L, lung SCC | 6 × 5 × 5 | 72/59/43; 0.7–0.8 | 130 |
2 | 57 | F | T3N1M0 | 80 | R, lower lung adenocarcinoma | 6 × 6 × 5 | 76/45/52; 0.8 | 140 |
3 | 59 | M | T3N1M1 | 70 | L, lower lung adenocarcinoma | 6 × 5 × 4 | 77/20; 0.7 | 140 |
4 | 59 | M | T3N2M0 | 70 | L, lung SCC | 5 × 5 × 4 | 66/62; 0.8 | 150 |
5 | 73 | M | T2N2M0 | 80 | R, lower lung adenocarcinoma with mediastinal LNM | 6 × 7 × 6 | 63/24; 0.8 | 140 |
6 | 70 | M | T3N1M1 | 70 | L, lung SCC with brain metastases | 5 × 5 × 4 | 45; 0.7 | 130 |
7 | 54 | M | T3N1M0 | 60 | L, lung poorly differentiated SCC | 8 × 7 × 5 | 100/40; 0.6 | 150 |
8 | 81 | M | T3N1M0 | 70 | R, lower lung adenocarcinoma with vertebral metastases | 6 × 5 × 5 | 65/45; 0.8 | 140 |
9 | 66 | F | T4N1M0 | 80 | R, lower lung SCC | 6 × 5 × 4 | 70/62; 0.7 | 130 |
10 | 67 | M | T2N1M1 | 70 | R, upper lung SCC with LNM | 4 × 4 × 3 | 48/20/14; 0.8 | 130 |
11 | 73 | M | T2N1M0 | 60 | L, lung SCC in situ recurrence after 1 y | 5 × 5 × 4 | 62/40; 0.8 | 140 |
12 | 78 | F | T2N0M0 | 70 | R, upper lung squamous | 3 × 1 × 2 | 23/40; 0.7 | 140 |
13 | 65 | F | T4N2M0 | 70 | SCC with mediastinal lymph node metastases | 7 × 6 × 6 | 89; 0.7 | 130 |
14 | 75 | M | T3N1M0 | 60 | Adenocarcinoma | 5 × 6 × 5 | 19/40; 0.7 | 130 |
15 | 66 | M | T3N2M1 | 80 | R, upper lung adenocarcinoma with vertebral metastases | 7 × 5 × 4 | 78; 0.6 | 160 |
16 | 60 | F | T2N1M1 | 70 | R, upper lung adenocarcinoma with adrenal metastasis | 6 × 5 × 5 | 70; 0.8 | 140 |
17 | 57 | M | T4N1M1 | 75 | L, lung SCC associated with vertebral metastases | 5 × 5 × 3 | 41/36; 0.8 | 130 |
18 | 64 | M | T3N2M0 | 80 | R, lung moderately differentiated SCC with mediastinal LNM | 4 × 5 × 5 | 52; 0.8 | 120 |